Trials / Terminated
TerminatedNCT04424914
Global Prevalence of ATTR-CM in Participants With HFpEF
GLOBAL PREVALENCE OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) IN PARTICIPANTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF)
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 347 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Not accepted
Summary
This study is a global, multi-center study designed to estimate the global prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM) within a clinically at risk population \[participants with heart failure with preserved ejection fraction (HFpEF)\].
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Scintigraphy | scintigraphy |
Timeline
- Start date
- 2020-12-30
- Primary completion
- 2023-06-02
- Completion
- 2023-06-02
- First posted
- 2020-06-11
- Last updated
- 2024-07-19
- Results posted
- 2024-07-19
Locations
51 sites across 8 countries: United States, Canada, France, Italy, Japan, Poland, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT04424914. Inclusion in this directory is not an endorsement.